Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 10/20 | 0.46 |
| ▸ | JAK2 | O60674 | 9/20 | 0.46 |
| ▸ | JAK1 | P23458 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706653 | 0.79 | TYK2 (0.62) | TYK2JAK2JAK1RAB9A | |
| SCHEMBL1706179 | 0.76 | TYK2 (0.59) | TYK2JAK2JAK1CYP3A4L3MBTL1 | |
| SCHEMBL16320788 | 0.75 | L3MBTL1 (0.55) | TYK2JAK2JAK1L3MBTL1TLR7 | |
| SCHEMBL23461777 | 0.75 | KDM4E (0.37) | TYK2RAB9A | |
| SCHEMBL1706720 | 0.74 | TYK2 (0.55) | TYK2JAK2JAK1CYP3A4MEN1 | |
| SCHEMBL16649977 | 0.74 | RAB9A (0.48) | TYK2JAK2JAK1RAB9AMEN1 | |
| SCHEMBL3516779 | 0.74 | LCK (0.51) | TYK2JAK2JAK1L3MBTL1RAB9A | |
| SCHEMBL1706027 | 0.73 | KCNQ3 (0.43) | CYP3A4RAB9AKMT2APOLB | |
| SCHEMBL1707688 | 0.73 | TYK2 (0.70) | TYK2JAK2JAK1CYP3A4 | |
| SCHEMBL29090445 | 0.71 | TYK2 (0.49) | TYK2JAK2JAK1CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TYK2 21/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.